UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/534,187	11/09/2005	Richard J. Jenny	02-1049-B	5272
20306 7590 01/04/2008 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE			EXAMINER	
			HANLEY, SUSAN MARIE	
	32ND FLOOR CHICAGO, IL 60606		ART UNIT	PAPER NUMBER
CITICAGO, IL			1651	
			MAIL DATE	DELIVERY MODE
			01/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		T			
;	Application No.	Applicant(s)			
	10/534,187	JENNY ET AL.			
Office Action Summary	Examiner	Art Unit			
	Susan Hanley	1651			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the o	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w. - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirce will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status		•			
1) Responsive to communication(s) filed on <u>09 Ja</u>		•			
,—	·				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Disposition of Claims					
4) ☐ Claim(s) 1-29 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-29 are subject to restriction and/or expressions.	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction.	epted or b) objected to by the drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).			
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	e Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage			
Attachment(s)		(57.5 44.6)			
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>5/6/05</u>. 	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	ate			

Application/Control Number:

10/534,187

Art Unit: 1651

Page 2

DETAILED ACTION

Election/Restrictions

This application contains claims directed to more than one species of the generic invention.

These species are deemed to lack unity of invention because they are not so linked as to form a

single general inventive concept under PCT Rule 13.1.

The species are as follows:

I. Applicant is required to elect the enzymatic activity being determined:

A. tissue factor; or

B. factor VIIa.

II. Applicant is required to elect the variables R_1 , R_2 , R_3 , R_4 and R_5 for the chromagenic

substrate, as in claim 2 or 16. Applicant is required to make the specie elections with the

caution that the elected specie must be a specific compound disclosed per se or that it may

be subject to a New Matter rejection.

Applicant is required, in reply to this action, to elect a single species to which the claims

shall be restricted if no generic claim is finally held to be allowable. The reply must also identify

the claims readable on the elected species, including any claims subsequently added. An argument

that a claim is allowable or that all claims are generic is considered non-responsive unless

accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to

additional species which are written in dependent form or otherwise include all the limitations of an

10/534,187 Art Unit: 1651

allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner: Claims 2-14 correspond to Specie Ia; Claims 16-29 correspond to Specie Ib;

Claims 2-4 and 16-18 correspond to Specie election II.

The following claim(s) are generic: No claim is generic.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

For specie election I, the methods A and B require a desire to obtain a sample having a specific analyte (e.g. clotting factor). The recited clotting factors represent structurally different biomolecules having distinct substrates, mechanisms of action and different functions in the clotting cascade. The selection of analyte directs the generation of a standard curve that could not be utilized for the other analyte.

For specie II, the selection of R groups defines structurally different compounds having distinct properties including the wavelength of absorption and emission. For example, the selection of R groups having more conjugated moieties will significantly influence the absorption/emission wavelengths which will affect the detection aspect of the claimed assay.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the

Art Unit: 1651

inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hanley whose telephone number is 571-272-2508. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/534,187

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Susan Hanley Examiner Art Unit 1651 SANDRA E. SAUCIER PRIMARY EXAMINER